News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Merck & Co., Inc. (JOBS) Pulls Bid for EU Approval of Zolinza
February 17, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, Feb 17 (Reuters) - Merck & Co has withdrawn its bid to get EU approval for its cutaneous T-cell lymphoma drug Zolinza, said the European regulator the EMEA.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
Merck & Co.
MORE ON THIS TOPIC
Insights
From Two Trials to One, Sponsors Face a Higher Standard
March 12, 2026
·
1 min read
·
Jennifer C. Smith-Parker
GLP-1
Novo Hit With FDA Warning Letter for Unreported Ozempic Safety Signals
March 11, 2026
·
2 min read
·
Tristan Manalac
Duchenne muscular dystrophy
Capricor Shares Rise as FDA Sets August Decision Date for Rejected Duchenne Therapy
March 11, 2026
·
2 min read
·
Tristan Manalac
Podcast
Prasad Out at FDA, Lawmaker Takes Action on Rare Disease Rejections and a Spate of Obesity Data
March 11, 2026
·
1 min read
·
Heather McKenzie
